Nevertheless, for the development of effective combinatorial chemotherapeutics, retaining enzymatic activity of TP may be necessary as it catalyzes an important step in activation of fluoropyrimidine-based agents such as capecitabine, which has been proposed as alternative treatment for advanced NSCLC [8]. The gene discussed is TYMP; the disease is non-small cell lung carcinoma.